Assessment of Luminal and Basal Phenotypes in Bladder Cancer

Charles C. Guo; Jolanta Bondaruk; Hui Yao; Ziqiao Wang; Li Zhang; Sangkyou Lee; June Goo Lee; David Cogdell; Miao Zhang; Guoliang Yang; Vipulkumar Dadhania; Woonyoung Choi; Peng Wei; Jianjun Gao; Dan Theodorescu; Christopher Logothetis; Colin Dinney; Marek Kimmel; John N. Weinstein; David J. McConkey; Bogdan Czerniak

doi:10.1038/s41598-020-66747-7

Assessment of Luminal and Basal Phenotypes in Bladder Cancer

Charles C. Guo, Jolanta Bondaruk, Hui Yao, Ziqiao Wang, Li Zhang, Sangkyou Lee, June Goo Lee, David Cogdell, Miao Zhang, Guoliang Yang, Vipulkumar Dadhania, Woonyoung Choi, Peng Wei, Jianjun Gao, Dan Theodorescu, Christopher Logothetis, Colin Dinney, Marek Kimmel, John N. Weinstein, David J. McConkeyBogdan Czerniak

School of Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80–94% sensitivity and 83–93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.

Original language	English (US)
Article number	9743
Journal	Scientific reports
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41598-020-66747-7
State	Published - Dec 1 2020

ASJC Scopus subject areas

General

Access to Document

10.1038/s41598-020-66747-7

Cite this

Guo, C. C., Bondaruk, J., Yao, H., Wang, Z., Zhang, L., Lee, S., Lee, J. G., Cogdell, D., Zhang, M., Yang, G., Dadhania, V., Choi, W., Wei, P., Gao, J., Theodorescu, D., Logothetis, C., Dinney, C., Kimmel, M., Weinstein, J. N., ... Czerniak, B. (2020). Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific reports, 10(1), Article 9743. https://doi.org/10.1038/s41598-020-66747-7

Guo, CC, Bondaruk, J, Yao, H, Wang, Z, Zhang, L, Lee, S, Lee, JG, Cogdell, D, Zhang, M, Yang, G, Dadhania, V, Choi, W, Wei, P, Gao, J, Theodorescu, D, Logothetis, C, Dinney, C, Kimmel, M, Weinstein, JN, McConkey, DJ & Czerniak, B 2020, 'Assessment of Luminal and Basal Phenotypes in Bladder Cancer', Scientific reports, vol. 10, no. 1, 9743. https://doi.org/10.1038/s41598-020-66747-7

@article{586b609010db4c42a4bd04f240079853,

title = "Assessment of Luminal and Basal Phenotypes in Bladder Cancer",

abstract = "Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80–94% sensitivity and 83–93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.",

author = "Guo, {Charles C.} and Jolanta Bondaruk and Hui Yao and Ziqiao Wang and Li Zhang and Sangkyou Lee and Lee, {June Goo} and David Cogdell and Miao Zhang and Guoliang Yang and Vipulkumar Dadhania and Woonyoung Choi and Peng Wei and Jianjun Gao and Dan Theodorescu and Christopher Logothetis and Colin Dinney and Marek Kimmel and Weinstein, {John N.} and McConkey, {David J.} and Bogdan Czerniak",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41598-020-66747-7",

language = "English (US)",

volume = "10",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Assessment of Luminal and Basal Phenotypes in Bladder Cancer

AU - Guo, Charles C.

AU - Bondaruk, Jolanta

AU - Yao, Hui

AU - Wang, Ziqiao

AU - Zhang, Li

AU - Lee, Sangkyou

AU - Lee, June Goo

AU - Cogdell, David

AU - Zhang, Miao

AU - Yang, Guoliang

AU - Dadhania, Vipulkumar

AU - Choi, Woonyoung

AU - Wei, Peng

AU - Gao, Jianjun

AU - Theodorescu, Dan

AU - Logothetis, Christopher

AU - Dinney, Colin

AU - Kimmel, Marek

AU - Weinstein, John N.

AU - McConkey, David J.

AU - Czerniak, Bogdan

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80–94% sensitivity and 83–93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.

AB - Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80–94% sensitivity and 83–93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85086596334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086596334&partnerID=8YFLogxK

U2 - 10.1038/s41598-020-66747-7

DO - 10.1038/s41598-020-66747-7

M3 - Article

C2 - 32546765

AN - SCOPUS:85086596334

SN - 2045-2322

VL - 10

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 9743

ER -

Assessment of Luminal and Basal Phenotypes in Bladder Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this